PIA Overview:

Neuropsychiatric Syndromes

Executive Committee

Co-Chair: Ross Baker
Co-Chair: Corinne Fischer
Communications Chair: Jennifer R. Gatchel
Member-in-Training: Willem S. Eikelboom


Neuropsychiatric Syndromes (NPS) in Neurodegenerative Disease is widely acknowledged as a major public-health priority area in the field of neurodegenerative disease. Experts are reminded of the universal prevalence of these symptoms in Alzheimer’s and related conditions, the significant added disability for patients and caregivers associated with NPS and the relative scarcity of effective treatments for NPS. The PIA will focus on defining clinical entities that will serve as targets for research and treatment development in later years. Sub-groups related to specific NPS in Alzheimer’s disease, targeting depression, agitation, apathy, psychosis and sleep disorder, will work to develop a series of next steps to meet the PIA’s overall objective.  Additionally, subgroups will be encouraged to incorporate biomarkers and therapeutics as added foci in their groups.  We will continue to aim to produce high impact publications that further advance our field, enhance our collaborations with other organizations that have a similar mission and identify funding opportunities as it related to NPS in AD and related dementias.


Join the NPS LinkedIn group to be part of the conversation and see content applicable to your PIA.

On Twitter? Follow @ISTAART and use #NeuropsychPIA to share news and stay up to date on PIA activity.



Please log in to access expanded content for members.